Onyx Pharmaceuticals Inc: (NASD: ONXX)
$85.54
-3.26 (-3.67%)
Volume 960,263
Jun 19 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 85.45 - 88.80 |
| 52wk Low - High | 43.73 - 101.57 |
| Previous Close | 88.80 |
| Avg. Volume | 1,105,222 |
| Industry | MED-DRUGS |
| Market Cap | 6.46 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.15 |
| P/E (F1) | 0.00 |
| Current Year Est. | -2.46 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
112 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| P/E (F1) | NA |
| PEG Ratio | NA |
| Current Year Est. | -2.46 |
| Current Quarter Estimate | -0.62 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-07-2013 |
| EPS Last Year | -2.54 |
| Expected Earnings Growth | NA |
Company Description
Onyx Pharmaceuticals, Inc is developing innovative products for the treatment of cancer.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.62 | -0.70 | -2.46 | -0.29 |
| Number of Estimates | 5 | 5 | 5 | 5 |
| Low Estimate | -0.86 | -0.87 | -2.93 | -1.76 |
| High Estimate | -0.44 | -0.53 | -2.11 | NA |
| Year Ago EPS | -0.85 | -0.89 | -3.04 | -2.46 |
| EPS Growth | 26.82% | 21.57% | 18.95% | 88.39% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| ONYX PHARMA INC | ONXX | 88.80 | |
|
| JAZZ PHARMACEUT | JAZZ | 69.66 | |
|
| SALIX PHARM-LTD | SLXP | 66.83 | |
|
| SANTARUS INC | SNTS | 22.28 | |
|
| USANA HLTH SCI | USNA | 74.58 | |
|
| ARADIGM CORP | ARDM | 0.17 | |
|
| CELL THERAPEUT | CTIC | 1.33 | |
|
| DURECT CORP | DRRX | 0.83 | |
|
| ELAN CP PLC ADR | ELN | 13.78 | |
|
| FLAMEL TECH | FLML | 6.16 | |
|
Sector:Medical>> Industry:MED-DRUGS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Positive Data on Array Oncology Candidate
Jun 19, 2013
Positive Data on Bayer/Onyx's Nexavar
Jun 03, 2013
Wider-than-Expected Loss at ChemoCentryx
May 14, 2013
Good News for Cubist Pharmaceuticals
May 09, 2013
Narrower-than-Expected Loss at ArQule
May 09, 2013
Narrower Loss from Onyx, Guidance Maintained
May 08, 2013
Wider-than-Expected Loss at Corcept
May 07, 2013
Valeant Misses Earnings and Revenue Estimate in 1Q (Revised)
May 07, 2013
Financials
| EPS TTM | -2.54 |
| Sales | 362 |
| Net Income | -165 |
| Price/Earnings | NA |
| Price/Book | 5.52 |
| Price/Cash Flow | NA |
| Price/Sales | 14.83 |
News
Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013 Report - M2
Jun 19, 2013
Wall Street Reports Releases Research on Alexion, BioMarin, Onyx, Questcor and ImmunoGen - Close-Up Media
Jun 19, 2013
Global Kidney Cancer Drugs Market 2013 Report - M2
Jun 18, 2013
Onyx Pharmaceuticals (ONXX) Showing Bearish Technicals With Resistance At $92.96 - Freshbrewedmedia
Jun 18, 2013
Shares of Onyx Pharmaceuticals Under Pressure, Down 1.7% - Financial News Network Online - Market Movers
Jun 18, 2013
Onyx Pharmaceuticals Crosses Below its 10-day MA (ONXX) - Financial News Network Online - Moving Average Crossovers
Jun 17, 2013
The Top 5 Diseases Caused by Obesity - TheMotleyFool
Jun 16, 2013
Critical Alerts For Anheuser-Busch InBev, GlaxoSmithKline, Capital One, Safeway, and Onyx Pharmaceuticals Released By InvestorsObserver - Pr Newswire
Jun 14, 2013
Broker Recommendations
| Current ABR | 1.27 |
| ABR (Last Week) | 1.27 |
| # of recs in ABR | 15 |
| Average Target Price | 107.00 |
| Industry Rank by ABR | 112 out of 265 |
| Rank in Industry | 17 out of 95 |
